Company Profile of Chengdu Dorher Pharmaceutical Co., Ltd.

Chengdu Dorther Pharmaceutical CO., Ltd was established in March 2017, and core Business is process development and industrialization of API, intermediates of highly difficult generic and innovative drugs.At present, it has developed into three companies: Wenjiang Headquarters R&D Company, Deyang Pilot R&D Site and Yunnan Qujing Commercial Production Site. The headquarters of Chengdu Dorther Pharmaceutical is located in Chengdu Wenjiang, mainly engaged in CRO of advanced new drug intermediates and chiral amino acids. At present, the Chengdu R&D Center has a 3000 square meter R&D laboratory center equipped with various conventional reaction devices, which can complete research and development of chemicals ranging from grams to tens of kilograms. At the same time, the QC laboratory is equipped with multiple testing equipment such as HPLC, GC, LC-MS, optical rotation detector, and moisture detection, providing customers with high-quality products. Established a branch in Deyang in 2019, with a 1500 square meter pilot production center, equipped with 24 sets of 100L high and low temperature kettles, we mainly undertake the research and development and production of varieties from the Chengdu headquarters, as well as customized production of high value-added products. We can provide products ranging from tens of kilograms to hundreds of kilograms. The self built production base in Yunnan and the GMP cooperative production base in Shandong and Meishan mainly undertake the commercial production of our company's research and development varieties to meet the ton level needs of customers. Main product: Non-natural amino acids and derivatives Spiral and bridge ring containing heteroatoms Pyridazine derivatives, piperazine and morpholine derivatives Complex polysubstituted aromatic derivatives Advanced intermediates for generic drugs Advanced intermediates for generic drugs: Lifitegrast Calilazine hydrochloride LOXO-101